News

Cardiomyopathies currently have no cures, but many of these disorders are prime candidates for gene therapies.

Check out this list of the top five articles posted on Formulary Watch this year!

Take a look at the best performing print articles of 2024. This year's top article spotlights the surge of mRNA vaccines being developed for other diseases outside of COVID-19.

Liraglutide injection is now approved for adult and pediatric patients ages 10 and up, proving another option amid the GLP-1 shortage.

Historically, healthcare organizations have considered the contact center to be a cost center, a communications platform for conveying information to patients and plan members. Today, however, AI-enabled contact centers can be drivers of value, especially in a value-based care environment.

Up to half of obstructive sleep apnea patients taking Zepbound had no symptoms after one year of treatment, averaging 25 fewer breathing interruptions per hour.

The FDA recently approved the treatment by Novo Nordisk for hemophilia A or B with inhibitors, designed to prevent or reduce bleeding episodes in patients aged 12 and older.

Here’s what you missed this week on Managed Healthcare Executive.

Although the primary endpoint was not met in a phase 2 study of women who used CBD before a scan, researchers say CBD does have some anti-anxiety effects.

If approved, Molbreevi could be the first FDA-approved treatment for patients with autoimmune pulmonary alveolar proteinosis, a rare lung disease.

Menopausal gay, lesbian and bisexual women are more likely to report recent sexual activity with less vaginal symptoms than heterosexual women of the same age, a new study suggests.

Spending reached $4.86 trillion in 2023, a 7.5% increase from 2022 The growth in spending on hospital care was the highest since 1990.

Originally approved in 2009, Stelara patents began expiring in 2023, leading to an influx of recent biosimilars.

If approved, clesrovimab would be the first and only FDA approved single dose immunization for infants approved in time for next year's RSV season, which lasts from October to April.

Organon, the company behind Vtama, received FDA approval ahead of its scheduled date of March 12, 2025.

This latest approval is the second indication of the monoclonal antibody, Nemluvio. It was first approved in Aug. 2024 to treat patients with prurigo nodularis.

Here’s what you missed this week on Managed Healthcare Executive.

The new guidelines consist of 145 recommendations for treating and managing premature ovarian insufficiency syndrome, which affects an estimated 4% of women under the age of 40 worldwide.

Research at the annual meeting of the American Society of Hematology evaluated patient and caregiver perspectives on gene therapies for sickle cell disease, which offer great potential but have had slow uptake.

Researchers at Brigham and Women’s Hospital Harvard Medical School looked at clinical trials and compared these biologics to placebos to see how their treatments improve and manage severe asthma.

Researchers have compiled a list of chemicals commonly found in plastics, including benzophenones, chlorinated paraffins and PFAS, known as “forever chemicals,” and they say there might be a connection to breast cancer.

Researchers are investigating the therapy as a treatment for B-cell malignancies, but they might also investigate as a treatment for multiple sclerosis and lupus.

Authorities have named Mangione, 26, as a person of interest in last week’s fatal shooting of United Healthcare CEO Brian Thompson in Manhattan. He was taken into custody at a McDonald’s in Altoona, Pennsylvania around 9 a.m. ET, officials said.

Here’s what you missed this week on Managed Healthcare Executive.

Aerobic exercise, particularly static exercises like yoga and stretching, performed 70 to 90 minutes three times a week over eight to 10 weeks, can significantly improve sleep disorders in menopausal women.

The combination of Columvi, gemcitabine and oxaliplatin is the first CD20xCD3 bispecific antibody to show positive results in a randomized diffuse large B-cell lymphoma phase 3 trial. The FDA’s decision is expected by July 20, 2025.